Moxonidine in Patients Undergoing Vascular Surgery

Phase 3TerminatedNCT00244504

University Hospital, Basel, Switzerland141 enrolled

Overview

Investigating the perioperative effect of moxonidine. In a randomized double-blind fashion, patients undergoing vascular surgery will receive moxonidine 0.2 mg or placebo from the day before surgery until day 4 after surgery. Holter-EKG for 48 h, starting just before surgery. Repeated 12-lead EKG, measurements of Troponin I and BNP, clinical visitations, follow-up interviews at 6 and 12 months

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

141

Conditions

Cardiac Disease Vascular Surgery

Interventions

moxonidineDRUG

moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * abdominal aortic or peripheral vascular surgery Exclusion Criteria: * unstable angina, * severe symptomatic heart failure (NYHA IV) * systolic blood pressure at rest \< 100 mmHg * bradycardia (\<50/min) * higher grade AV heart block * creatinine clearance \< 30 ml/min * pregnancy * no consent

Locations (1)

University hospital

Basel, CH, Switzerland

Outcomes

Primary Outcomes

over-all mortality

Time frame: 30 days and 12 months

Secondary Outcomes

Ischemia detected by Holter-ECG ST alterations or troponin T elevation

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.